3Subramaniam B, Panzica P J, Novack V, et al. Continuous periop- erative insulin infusion decreases major cardiovascular events in patients undergoing vascular surgery: a prospective, randomized trial[J]. Anesthesiology, 2009, 110(5): 970-977.
4Gupta P, Whiteside W, Sabati A, et al. Safety and efficacy of pro- longed dexmedetomidine use in critically ill children with heart disease[J]. Pediatr Crit Care Med, 2012, 13(6): 660-666.
5Chrysostomou C, Schmitt C G. Dexmedetomidine: sedation, anal- gesia and beyond[J]. Expert Opin Drug Metab Toxicol, 2008, 4(5): 619-627.
6Dahmani S, Rouelle D, Gressens P, et al. Characterization of the postconditioning effect of dexmedetomidine in mouse organotyp- ic hippocampal slice cultures exposed to oxygen and glucose deprivation[J]. Anesthesiology, 2010, 112(2): 373-383.
7Bicer C, Esmaoglu A, Akin A, et al. Dexmedetomidine and me-peridine prevent postanaesthetic shivering[J]. Eur J Anaesthesiol, 2006, 23(2): 149-153.
8Halt J E, Uhrich T D, Barney J A, et al. Sedative, amnestic, and analgesic properties of small-dose dexmedetomidine infusions [J]. Anesth Analg, 2000, 90(3): 699-705.
9Khann ZP,Ferguson CN,Jones RM. Alpha-2 and imidazoline receptor ag-onists. Their pharmacology and therapeutic role[ J]. Anesthesia, 1999 ;54(2):146-65.
10KunisawaT,Nagata 0, Nagashima M,e/ al. Dexmedetomidine suppressesthe decrease in blood pressure during anesthetic induction and blunts thecardiovascular response to tracheal intubation[ J]. J Clin Anesth,2009;21(3):194-9.
